Literature DB >> 21715490

Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01.

Yuxing Li1, Sijy O'Dell, Laura M Walker, Xueling Wu, Javier Guenaga, Yu Feng, Stephen D Schmidt, Krisha McKee, Mark K Louder, Julie E Ledgerwood, Barney S Graham, Barton F Haynes, Dennis R Burton, Richard T Wyatt, John R Mascola.   

Abstract

The structure of VRC01 in complex with the HIV-1 gp120 core reveals that this broadly neutralizing CD4 binding site (CD4bs) antibody partially mimics the interaction of the primary virus receptor, CD4, with gp120. Here, we extended the investigation of the VRC01-gp120 core interaction to the biologically relevant viral spike to better understand the mechanism of VRC01-mediated neutralization and to define viral elements associated with neutralization resistance. In contrast to the interaction of CD4 or the CD4bs monoclonal antibody (MAb) b12 with the HIV-1 envelope glycoprotein (Env), occlusion of the VRC01 epitope by quaternary constraints was not a major factor limiting neutralization. Mutagenesis studies indicated that VRC01 contacts within the gp120 loop D, the CD4 binding loop, and the V5 region were necessary for optimal VRC01 neutralization, as suggested by the crystal structure. In contrast to interactions with the soluble gp120 monomer, VRC01 interaction with the native viral spike did not occur in a CD4-like manner; VRC01 did not induce gp120 shedding from the Env spike or enhance gp41 membrane proximal external region (MPER)-directed antibody binding to the Env spike. Finally, VRC01 did not display significant reactivity with human antigens, boding well for potential in vivo applications. The data indicate that VRC01 interacts with gp120 in the context of the functional spike in a manner distinct from that of CD4. It achieves potent neutralization by precisely targeting the CD4bs without requiring alterations of Env spike configuration and by avoiding steric constraints imposed by the quaternary structure of the functional Env spike.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21715490      PMCID: PMC3165784          DOI: 10.1128/JVI.00754-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  76 in total

1.  Oligomeric organization of gp120 on infectious human immunodeficiency virus type 1 particles.

Authors:  C D Weiss; J A Levy; J M White
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

2.  Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1.

Authors:  A Pinter; W J Honnen; S A Tilley; C Bona; H Zaghouani; M K Gorny; S Zolla-Pazner
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

3.  Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule.

Authors:  J S McDougal; M S Kennedy; J M Sligh; S P Cort; A Mawle; J K Nicholson
Journal:  Science       Date:  1986-01-24       Impact factor: 47.728

4.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

5.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection.

Authors:  Douglas D Richman; Terri Wrin; Susan J Little; Christos J Petropoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-18       Impact factor: 11.205

6.  T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV.

Authors:  D Klatzmann; E Champagne; S Chamaret; J Gruest; D Guetard; T Hercend; J C Gluckman; L Montagnier
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

7.  Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins.

Authors:  Zhihai Si; Navid Madani; Jason M Cox; Jason J Chruma; Jeffrey C Klein; Arne Schön; Ngoc Phan; Liping Wang; Alyssa C Biorn; Simon Cocklin; Irwin Chaiken; Ernesto Freire; Amos B Smith; Joseph G Sodroski
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-29       Impact factor: 11.205

8.  The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus.

Authors:  A G Dalgleish; P C Beverley; P R Clapham; D H Crawford; M F Greaves; R A Weiss
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

9.  Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein.

Authors:  P L Earl; R W Doms; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

10.  Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition.

Authors:  Markus Koch; Marie Pancera; Peter D Kwong; Peter Kolchinsky; Christoph Grundner; Liping Wang; Wayne A Hendrickson; Joseph Sodroski; Richard Wyatt
Journal:  Virology       Date:  2003-09-01       Impact factor: 3.616

View more
  153 in total

1.  Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design.

Authors:  Mattia Bonsignori; David C Montefiori; Xueling Wu; Xi Chen; Kwan-Ki Hwang; Chun-Yen Tsao; Daniel M Kozink; Robert J Parks; Georgia D Tomaras; John A Crump; Saidi H Kapiga; Noel E Sam; Peter D Kwong; Thomas B Kepler; Hua-Xin Liao; John R Mascola; Barton F Haynes
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

2.  Signature biochemical properties of broadly cross-reactive HIV-1 neutralizing antibodies in human plasma.

Authors:  Mohammad M Sajadi; George K Lewis; Michael S Seaman; Yongjun Guan; Robert R Redfield; Anthony L DeVico
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

Review 3.  Neutralizing antibodies and control of HIV: moves and countermoves.

Authors:  Ann J Hessell; Nancy L Haigwood
Journal:  Curr HIV/AIDS Rep       Date:  2012-03       Impact factor: 5.071

4.  Solution structure, conformational dynamics, and CD4-induced activation in full-length, glycosylated, monomeric HIV gp120.

Authors:  Miklos Guttman; Maria Kahn; Natalie K Garcia; Shiu-Lok Hu; Kelly K Lee
Journal:  J Virol       Date:  2012-06-06       Impact factor: 5.103

5.  HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120.

Authors:  James M Kovacs; Joseph P Nkolola; Hanqin Peng; Ann Cheung; James Perry; Caroline A Miller; Michael S Seaman; Dan H Barouch; Bing Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-05       Impact factor: 11.205

6.  Efficiency of neutralizing antibodies targeting the CD4-binding site: influence of conformational masking by the V2 loop in R5-tropic clade C simian-human immunodeficiency virus.

Authors:  Jennifer D Watkins; Juan Diaz-Rodriguez; Nagadenahalli B Siddappa; Davide Corti; Ruth M Ruprecht
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

7.  Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies.

Authors:  Allan deCamp; Peter Hraber; Robert T Bailer; Michael S Seaman; Christina Ochsenbauer; John Kappes; Raphael Gottardo; Paul Edlefsen; Steve Self; Haili Tang; Kelli Greene; Hongmei Gao; Xiaoju Daniell; Marcella Sarzotti-Kelsoe; Miroslaw K Gorny; Susan Zolla-Pazner; Celia C LaBranche; John R Mascola; Bette T Korber; David C Montefiori
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

8.  The griffithsin dimer is required for high-potency inhibition of HIV-1: evidence for manipulation of the structure of gp120 as part of the griffithsin dimer mechanism.

Authors:  Jie Xue; Bart Hoorelbeke; Ioannis Kagiampakis; Borries Demeler; Jan Balzarini; Patricia J Liwang
Journal:  Antimicrob Agents Chemother       Date:  2013-06-10       Impact factor: 5.191

9.  Optimized and enhanced DNA plasmid vector based in vivo construction of a neutralizing anti-HIV-1 envelope glycoprotein Fab.

Authors:  Kar Muthumani; Seleeke Flingai; Megan Wise; Colleen Tingey; Kenneth E Ugen; David B Weiner
Journal:  Hum Vaccin Immunother       Date:  2013-09-17       Impact factor: 3.452

10.  An Antigenic Atlas of HIV-1 Escape from Broadly Neutralizing Antibodies Distinguishes Functional and Structural Epitopes.

Authors:  Adam S Dingens; Dana Arenz; Haidyn Weight; Julie Overbaugh; Jesse D Bloom
Journal:  Immunity       Date:  2019-01-29       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.